Literature DB >> 34233448

Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase 1b study.

Paolo Strati1, Sven De Vos2, Jia Ruan3, Kami J Maddocks4, Christopher R Flowers5, Simon Rule6, Priti Patel7, Yan Xu7, Helen Wei7, Melanie M Frigault7, Roser Calvo8, Martin J S Dyer9.   

Abstract

Not available.

Entities:  

Year:  2021        PMID： 34233448     DOI： 10.3324/haematol.2021.278654

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  2 in total

Review 1.  BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.

Authors:  Aqu Alu; Hong Lei; Xuejiao Han; Yuquan Wei; Xiawei Wei
Journal:  J Hematol Oncol       Date:  2022-10-01       Impact factor: 23.168

Review 2.  Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies.

Authors:  Yazeed Sawalha
Journal:  J Pers Med       Date:  2021-12-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.